About 9 results found for searched term "MET kinase-IN-4" (0.13 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M30821 | MET kinase-IN-4 | c-Met |
| MET kinase-IN-4 is an orally active Met kinase inhibitor. MET kinase-IN-4 has potent Met kinase inhibitory activity with an IC50 value of 1.9 nM. MET kinase-IN-4 can be used for the research of cancer. | ||
| M1682 | BMS-777607 | c-Met |
| BMS 817378; CAS# 1025720-94-8 | ||
| BMS-777607 is a selective and potent small-molecule met kinase inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively. | ||
| M1765 | Crizotinib (PF-02341066) | c-Met |
| Crizotinib | ||
| Crizotinib (PF-02341066) is a potent, orally bioavailable, ATP-competitive small-molecule inhibitor of c-Met kinase and ALK (anaplastic lymphoma kinase) with IC50 values to be 4 and 25 nM for C-Met and ALK resepectively. | ||
| M14173 | GW806742X hydrochloride | Necroptosis |
| GW806742X hydrochloride is an ATP mimetic and potent inhibitor of MLKL and necroptosis, slowing down MLKL membrane translocation and binding to the MLKL pseudokinase domain with a Kd value of 9.3 μM. GW806742X hydrochloride has anti-VEGFR2 activity (IC50=2 nM). GW806742X hydrochloride has anti-VEGFR2 activity (IC50=2 nM). | ||
| M20606 | SAR125844 | c-Met |
| SAR125844 is a potent intravenously active and highly selective MET kinase inhibitor, displaying nanomolar activity against the wild-type kinase (IC50 value of 4.2 nmol/L) and H1094Y, Y1235D, M1250T, L1195V, and D1228H kinase domain mutants (IC50 values of 0.22, 1.7, 6.5, 65, and 81 nmol/L, respectively). | ||
| M20652 | JNJ-38877618 | c-Met |
| JNJ-38877618 (OMO-1) is a potent, highly selective, orally bioavailable MET kinase inhibitor with binding affinity (Kd) of 1.4 nM and enzyme inhibitory activity against wt and M1268T mutant MET (2 and 3 nM IC50). | ||
| M20743 | AMG-1 | c-Met |
| c-Met/RON Dual Kinase Inhibitor, RON-IN-1 | ||
| AMG-1 (c-Met/RON Dual Kinase Inhibitor, RON-IN-1) is a potent inhibitor of human c-Met and RON with IC50 of 4 nM and 9 nM, respectively. | ||
| M54609 | Capmatinib dihydrochloride hydrate | c-Met |
| INC280 dihydrochloride hydrate; INCB-28060 dihydrochloride hydrate | ||
| Capmatinib dihydrochloride hydrate is a potent, orally active, selective, ATP-competitive c-Met kinase inhibitor (IC50=0.13 nM) that inhibits the phosphorylation of c-MET, as well as downstream effector proteins of the c-MET pathway, such as ERK1/2, AKT, FAK, In addition, Capmatinib dihydrochloride hydrate effectively inhibited the proliferation and migration of c-Met-dependent tumor cells, induced apoptosis, and demonstrated antitumor activity in a mouse model of tumor. Capmatinib dihydrochloride hydrate is mainly metabolized by CYP3A4 and aldehyde oxidase. | ||
| M57192 | MET kinase-IN-2 | c-Met |
| MET kinase-IN-2 is a potent, selective, orally bioavailable MET kinase inhibitor with an IC50 of 7.4 nM. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
